ABSTRACT
Objective To systematically evaluate the direction of any potential causal effect between sleep and adiposity traits.
Methods Two-sample Mendelian randomization (MR) was used to assess the association of genetically predicted sleep traits on adiposity and vice versa. Using data from UK Biobank and 23andme, the sleep traits explored were morning-preference (chronotype) (N=697,828), insomnia (N=1,331,010), sleep duration (N=446, 118), napping (N=452,633) and daytime-sleepiness (N=452,071). Using data from the GIANT and EGG consortia, the adiposity traits explored were adult BMI, hip circumference (HC), waist circumference (WC), waist-to-hip ratio (WHR) (N=322,154) and child-BMI (N=35,668).
Results We found evidence that insomnia symptoms increased mean WC, BMI and WHR (difference in means WC=0.39 SD (95% CI=0.13, 0.64), BMI=0.47 SD (0.22, 0.73) and WHR=0.34 SD (0.16, 0.52)). Napping increased mean WHR (0.23 SD (0.08, 0.39). Higher HC, WC, and adult-BMI increased odds of daytime-sleepiness (HC=0.02 SD (0.01, 0.04), WC=0.04 SD (0.01, 0.06) and BMI 0.02 SD (0.00, 0.04), respectively). We also found that higher mean child-BMI resulted in lower odds of napping (−0.01 SD (0.02, 0.00).
Conclusions The effects of insomnia on adiposity, and adiposity on daytime-sleepiness, suggest that poor sleep and weight gain may contribute to a feedback loop that could be detrimental to overall health.
Competing Interest Statement
DAL has received support from Roche Diagnostics and Medtronic Ltd for research unrelated to that presented here. TR has received grants from Daiichi-Sankyo and Amgen to attend educational workshops. All other authors have no competing interests to declare.
Funding Statement
BH is funded by an Above & Beyond breast cancer legacy grant from University Hospitals Bristol NHS Foundation Trust (www.aboveandbeyond.org.uk). MV is supported by the University of Bristol Alumni Fund (Professor Sir Eric Thomas Scholarship). TR is supported by a National Institute of Health Research Development and Skills Enhancement Award (NIHR302363). RCR is a de Pass Vice Chancellor's Research Fellow. RMM is supported by a Cancer Research UK (C18281/A19169) programme grant (the Integrative Cancer Epidemiology Programme) (www.cancerresearchuk.org/funding-for-researchers). BH, TR, RMM, DAL and RCR work in the Medical Research Council Integrative Epidemiology Unit at the University of Bristol supported by the Medical Research Council (MC_UU_00011/1 and MC_UU_00011/6) (www.mrc.ukri.org) and the University of Bristol. RMM and DAL are also supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, which is funded by the National Institute for Health Research (NIHR) (www.nihr.ac.uk) and is a partnership between University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. DAL is an NIHR Senior Investigator (NF-0616-10102). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used only openly available human data that were originally available at: https://sleep.hugeamp.org/dinspector.html?dataset=GWAS_UKBB_eu https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files http://egg-consortium.org/childhood-bmi.html
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
FUNDING BH is funded by an Above & Beyond breast cancer legacy grant from University Hospitals Bristol NHS Foundation Trust (www.aboveandbeyond.org.uk). MV is supported by the University of Bristol Alumni Fund (Professor Sir Eric Thomas Scholarship). TR is supported by a National Institute of Health Research Development and Skills Enhancement Award (NIHR302363). RCR is a de Pass Vice Chancellor’s Research Fellow. RMM is supported by a Cancer Research UK (C18281/A19169) programme grant (the Integrative Cancer Epidemiology Programme) (www.cancerresearchuk.org/funding-for-researchers). BH, TR, RMM, DAL and RCR work in the Medical Research Council Integrative Epidemiology Unit at the University of Bristol supported by the Medical Research Council (MC_UU_00011/1 and MC_UU_00011/6) (www.mrc.ukri.org) and the University of Bristol. RMM and DAL are also supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, which is funded by the National Institute for Health Research (NIHR) (www.nihr.ac.uk) and is a partnership between University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. DAL is an NIHR Senior Investigator (NF-0616-10102). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
CONFLICTS OF INTEREST I have read the journal’s policy and the authors of this manuscript have the following competing interests: DAL has received support from Roche Diagnostics and Medtronic Ltd for research unrelated to that presented here. TR has received grants from Daiichi-Sankyo and Amgen to attend educational workshops. All other authors have no competing interests to declare.
Data Availability
Summary data for the morning-preference, insomnia, sleep duration, napping, and daytime-sleepiness GWAS used in this study are available at: https://sleep.hugeamp.org/dinspector.html?dataset=GWAS_UKBB_eu Summary data for the adult-BMI, WC, HC and WHR GWAS used in this study are available at: https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files Summary data for the child-BMI GWAS used in this study is available at: http://egg-consortium.org/childhood-bmi.html
https://sleep.hugeamp.org/dinspector.html?dataset=GWAS_UKBB_eu
https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files